Advertisement

Bladder Cancer pp 235-262 | Cite as

Chemotherapy of Bladder Cancer

  • E. Messing
  • J. B. deKernion
Part of the Clinical Practice in Urology book series (PRACTICE UROLOG)

Abstract

Superficial bladder tumours (those not invading into muscle) represent by far the most common form of transitional cell carcinoma (TCC) (Koss 1975). They are usually papillary and of a low histological grade, although sessile tumours, which carry a somewhat worse prognosis, are not uncommon (deKernion and Skinner 1978).

Keywords

Bladder Cancer Bladder Tumor Transitional Cell Carcinoma Bladder Carcinoma Superficial Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alroy J, Teramura K, Miller AW, Pauli B, Gottesman JE, Flanagan M, Davidsohn I, Weinstein, RS (1978) Iso-antigens A, B, and H in urinary bladder carcinoma following radiotherapy. Cancer 41: 1739–1745PubMedGoogle Scholar
  2. Althausen AF, Prout GR, Jr, Daly JJ (1976). Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116: 575–580PubMedGoogle Scholar
  3. Ansfield F (1973) Treatment of tumours of the urinary tract. In: Ansfield F (ed) Chemotherapy of malignant neoplasms. Thomas, Springfield, 111, pp 289–290Google Scholar
  4. Antonaci S, Piccinno A, Lucivero G (1981) Effect of BCG cell-mediated cytotoxicity in bladder cancer patients following surgical treatment. Tumori 67: 177–182PubMedGoogle Scholar
  5. Asaki T, Matsumura Y, Takahashi T, Yoshimoto J, Kaneshige T, Fujita Y, Ohmori H (1980) The effects of intravesical instillation of thiotepa on the recurrence rate of bladder tumours. Acta Med Okayama 321: 43–49Google Scholar
  6. Banks MD, Pontes JE, Izbicki RM, Pierce JM (1977) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 757–760PubMedGoogle Scholar
  7. Bean MA, Pees H, Fogh J, Grabstald H, Oettgen HF (1974) Cytotoxicity of lymphocytes from patients with cancer of the urinary bladder. Detection by 3H-proline microcytotoxicity test. Int J Cancer 14: 186–197PubMedGoogle Scholar
  8. Bergman S, Javadpour N (1978) The cell surface antigens A, B, O(H) as an indicator of malignant potential in stage A bladder carcinoma: a preliminary report. J Urol 119: 49–51PubMedGoogle Scholar
  9. Bergsma CJ, Leary FJ (1976) Total bladder necrosis following intravesical formalin. In: Proceedings of the Annual Meeting of the American Urological Association, North Central Section, Annual Meeting, Palm Beach, Florida, 1976Google Scholar
  10. Billiau A (1981) The clinical value of interferon as antitumor agents. Eur J Cancer Clin Oncol 17: 949–967PubMedGoogle Scholar
  11. Bloom ET, Brown DE (1980) Detection of antigenic differences and similarities between human transitional cell carcinoma cell lines using rabbit antisera. Urol Res 8: 5–13PubMedGoogle Scholar
  12. Bloom ET, Ossorio RC, Brosman SA (1974) Cell mediated cytotoxicity against human bladder cancer. Int J Cancer 14: 326–332PubMedGoogle Scholar
  13. Bogden AE, Cobb WR, LePage DJ (1982) An in vitro method for testing chemotherapeutic agents against first transplant generation human tumor xenografts. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, pp 175–184Google Scholar
  14. Bonadonna G, Monfardini S, deLena M, Fossati-Bellani F, Baretta G (1972) Trials with Adriamycin. Results of 3 years study. In: Carter SK, DiMarcos A, Ghione M et al. (eds) International symposium on Adriamycin. Springer, Berlin Heidelberg New York, pp 139–152Google Scholar
  15. Bowen JG (1978) Transitional cell carcinoma: circulation tumor antigen correlated with presence absence of tumor (leukocyte migration assay). Natl Cancer Inst Mongr 49: 245–247Google Scholar
  16. Boxer RJ, Sofen H, Saxon A (1981) The detection of transitional cell bladder cancer antigen on established cell lines. Invest Urol 19: 70–74PubMedGoogle Scholar
  17. Boyd PJR, Burnand KG (1974) Site of bladder tumor recurrence. Lancet II: 1290-1292Google Scholar
  18. Bracken RB, Johnson DE, Von Eschenbach AC, Swanson DA, DeFuria D, Crooke S (1980) Role of intravesical Mitomycin C in the management of superficial bladder tumors. Urology 16: 11–15PubMedGoogle Scholar
  19. Brosman S (1980) Immunotherapy in bladder cancer. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 166–170Google Scholar
  20. Brosman S, Dorey F, Fahey J (1981) Intravesical BCG in superficial bladder cancer. In: Proceedings of the 7th Annual NBCP Investigator’s Workshop. Hershey, Pennsylvania, June 1981Google Scholar
  21. Burnand KG, Boyd PJR, Mayo MF, Shuttleworth KED, Lloyd-Davies RW (1976) Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell carcinoma. Br J Urol 48: 55–59PubMedGoogle Scholar
  22. Byar DP (1980) The Veterans Administration study of chemo prophylaxis for recurrent stage I bladder tumors: comparisons of placebo, pyridoxine and topical thiotepa. In: Pavone-Macaluso M, Smith PH, Edsmyr R (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 363–370Google Scholar
  23. Caldwell WL (1974) Carcinoma of the urinary bladder. JAMA 229: 1643PubMedGoogle Scholar
  24. Caldwell WL (1976) Radiotherapy: definitive, integrated and palliative therapy. Urol Clin North Am 3: 129–148PubMedGoogle Scholar
  25. Camacho F, Pinsky C, Kerr D, Whitmore W, Oettgen H (1980) Treatment of superficial bladder cancer with intravesical BCG. Proc Am Soc Clin Oncol 21: 359Google Scholar
  26. Chasko SB, Keuhnelian JG, Gutowski WT, Gray AF (1980) Spindle cell cancer of the bladder during cyclophosphamide therapy for Wegener’s granulomatosis. Am J Surg Pathol 4: 191–196PubMedGoogle Scholar
  27. Chodak GW, Straus FW, Schoenberg HW (1981) Simultaneous occurrence of transitional, squamous and adenocarcinoma of the bladder after 15 years of cyclophosphamide therapy. J Urol 125: 424–426PubMedGoogle Scholar
  28. Chopin DK, Bubbers JE, deKernion JB, Fahey JL (1984) Tumor associated antigens (TA A) on human bladder cancer defined by monoclonal antibodies. In: Proceedings of 10th Annual NBCP Investigators’ Workshop, Sarasota, Florida, 4–7 January, 1984Google Scholar
  29. Coates AS, Golovsky D, Freedman A (1981) Prolonged remission in recurrent bladder cancer after chemotherapy with cis-platinum. Med J Austr 1: 533–534Google Scholar
  30. Cole P (1975) Lower urinary tract. In: Schottenfeld D (ed) Cancer epidemiology and prevention. Thomas, Springfield, 111, pp 233–262Google Scholar
  31. Colleen S, Hellsten AE, Lindholm CE (1980) Intracavitary Epodyl for multiple, non-invasive, highly differentiated bladder tumors. Scan J Urol Nephrol 14: 43–45Google Scholar
  32. Collste L, Berlin T, Gronberg-Ohman I, Von Garrelts B, Wijkstrom H (1980) Long-term intracavitary Epodyl in multiple or extensive papillary tumors of the urinary bladder. In: Pavone-Maculoso M, Smith PH, Edsmyr R (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 335–336Google Scholar
  33. Confer D, Smith RB, Gillespie L (1977) Dramatic palliation for painful fixed bladder squamous cell carcinoma with 5-fluorouracil. J Urol 118: 483–484PubMedGoogle Scholar
  34. Cooper PH, Waisman J, Johnston WH, Skinner DG (1973) Severe atypia of transitional epithelium and carcinoma of the urinary bladder. Cancer 31: 1055–1060PubMedGoogle Scholar
  35. Cox CE, Cass AS, Boyce WH (1969) Bladder cancer: a 26 year review. J Urol 101: 550–558PubMedGoogle Scholar
  36. Cummings KB, Shipley WU, Einstein AE et al. (1979) Current concepts in the management of patients with deeply invasive bladder carcinoma. Semin Oncol 6: 220–228PubMedGoogle Scholar
  37. Daly JJ (1976) Carcinoma in situ of the urothelium. Urol Clin North Am 3: 87–105PubMedGoogle Scholar
  38. D’Aoust JC, Archambautt WA, Merrin CE, Rosenbaum PF, Crook ST (1980) Analysis of toxicities associated with long-term administration of cis-platinum to patients with urogenital tumors. Proc Am Assoc Cancer Res 21: 355Google Scholar
  39. Decenzo JM, Ledbetter GW (1976) The interaction of host immunocompetence and tumor aggressiveness in superficial bladder carcinoma. J Urol 115: 262–263PubMedGoogle Scholar
  40. DeFuria MD, Bracken RB, Johnson DE, Soloway MS, Merrin CE, Morgan LR, Miller HC, Crooke ST (1980) Phase I-II study of Mitomycin C topical therapy for low grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep 64: 225–230PubMedGoogle Scholar
  41. deKernion JB (1977) The chemotherapy of advanced bladder carcinoma. Cancer Res 37: 2771–2774PubMedGoogle Scholar
  42. deKernion JB, Skinner DG (1978) Epidemiology, diagnosis and staging of bladder cancer. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, pp 213–231Google Scholar
  43. deKernion JB, Stewart BH, Yagoda A (1978) Treatment of advanced bladder cancer. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, pp 284–294Google Scholar
  44. Droller JJ (1980) Transitional cell carcinoma: an overview. Urol Clin North Am 7: 731–733PubMedGoogle Scholar
  45. Duchek M (1980) Local treatment of uroepithelial bladder tumors with Adriamycin. In: Pavone- Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 323–326Google Scholar
  46. Duchek M, Edsmyr F, Nasland I (1980) 5-Fluorouracil in the treatment of recurrent cancer of the urinary bladder. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 399–400Google Scholar
  47. Durant JR (1980) Phase III adjuvant chemotherapy with cytoxan-Adriamycin-cw-platinum for resected transitional cell bladder carcinoma. In: Proceedings of the 6th NBCP Annual MeetingGoogle Scholar
  48. Edsmyr F, Berlin T, Boman J, Duchek M, Esposti PL, Gustavson H, Wikstrom H (1980) Intravesical therapy with Adriamycin in patients with superficial bladder tumors. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 321–322Google Scholar
  49. Edsmyr F, Andersson L, Esposti P (1984) Intravesical chemotherapy of carcinoma in situ in bladder cancer. Urology (Suppl) 23: 37–39Google Scholar
  50. Ek A, Colleen S (1980) Treatment of multiple non-invasive bladder tumours with intravesical Epodyl. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 337–342Google Scholar
  51. Elliott AY, Dombrovski S, Fraley EE (1978) Transitional cell carcinoma: fluorescent antibody binding to tumor cells. Natl Cancer Inst Mongr 49: 23Google Scholar
  52. England HR, Molland EA, Oliver RT, Blandy JP (1980) Flat carcinoma in situ of the bladder treated by systemic cyclophosphamide—a preliminary report. In: Pavone-Macaluso J, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 371–376Google Scholar
  53. Esquivel EL, Mackenzie AR, Whitmore WF (1965) Treatment of bladder tumors by instillation of thiotepa, Actinomycin D, or 5-fluorouracil. Invest Urol 2: 381PubMedGoogle Scholar
  54. Fair WR (1974) Formalin in the treatment of massive bladder hemorrhage. Urology 3: 573 - 577PubMedGoogle Scholar
  55. Fetter TB, Bogaev JH, McCuskey B, Seres JL (1959) Carcinoma of the bladder: sites of metastases. J Urol 81: 746–748PubMedGoogle Scholar
  56. Fidler IJ (1982) The role of host factors and tumor heterogeneity in the testing of therapeutic agents. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, pp 239–247Google Scholar
  57. Field AK, Tytell AA, Lampson GP, Hilleman MR (1967) Inducers of interferon and h st resistance. II. Multistranded synthetic polyneucleotide complexes. Proc Natl Acad Sci USA 58: 1004–1010Google Scholar
  58. Fradet Y, Cordon-Cardo C, Whitmore WF, Old LJ (1984) Definition of human bladder tumor subsets with monoclonal antibodies to tumor associated antigens. In: Proceedings of the 10th Annual NBCP Investigators Workshop. Sarasota, Florida, 4-7 January, 1984, p 37Google Scholar
  59. Frei E, Luce JK, Middleman E (1972) Clinical trials of Adriamycin. In: Carter SK, DiMarco A, Ghione A et al. (eds) International symposium on Adriamycin. Springer, Berlin Heidelberg New York, pp 153–164Google Scholar
  60. Friedell GH (1976) Carcinoma, carcinoma in situ and “early lesions” of the uterine cervix and urinary bladder: introduction and definitions. Cancer Res 36: 2482PubMedGoogle Scholar
  61. Gad-el Mawla N, Muggia PM, Hamza MR, El-Morsi B, Sherif M, Mansour MA, Khafagy M, El Sebai IT (1978) Chemotherapeutic management of carcinoma of the bilharzial bladder. A Phase II trial with hexamethylmelamine and VM-26. Cancer Treat Rep 62: 993–996PubMedGoogle Scholar
  62. Gammelgaard PA, Morgensen P, Lindbeck F (1980) Bladder instillation of Adriamycin in multiple recurrent noninvasive papillomatous bladder tumours. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 329–331Google Scholar
  63. Garnick B, Scade D, Israel M, Maxwell B, Richie JP (1984) Intravesical doxorubicin for prophylaxis in management of recurrent superficial bladder carcinoma. J Urol 131: 43–46PubMedGoogle Scholar
  64. Gavrell GJ, Lewis RW, Meehan WL, LeBlanc GA (1978) Intravesical thiotepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120: 410–411PubMedGoogle Scholar
  65. Ghoneim MA, and Awaad HK (1980) Results of treatment in carcinoma of the bilharzial bladder. J Urol 123: 850–852PubMedGoogle Scholar
  66. Gonwa TA, Corbett WT, Schey HM, Buckalew VM (1980) Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract. Ann Intern Med 93: 249–252PubMedGoogle Scholar
  67. Gozzo JJ, Cronin WJ, O’Brien P, Monaco AP (1980) Detection of tumor associated antigens in the urine of patients with bladder cancer. J Urol 125: 804–807Google Scholar
  68. Glucksman MA (1980) Bladder carcinoma after cyclophosphamide therapy. (Letter to the Editor). Urology 16: 553PubMedGoogle Scholar
  69. Green DF, Robinson MRG, Glashan R, Newling D, Dalesio O, Smith PH (1984) Does intravesical chemotherapy prevent invasive bladder cancer? J Urol 131: 33–35PubMedGoogle Scholar
  70. Grossman HB (1983) Hybridoma antibodies reactive with human bladder carcinoma cell surface antigens. J Urol 130: 610–615PubMedGoogle Scholar
  71. Hakala TR, Lange PH, Castro AB, Elliott A, Fraley EE (1974) Antibody induction of lymphocyte mediated cytoxicity against human transitional cell carcinomas of the gentitourinary tract. Cancer 34: 1929–1934PubMedGoogle Scholar
  72. Hall RR (1980a) Intravesical hyperthermia for transitional cell carcinoma of the bladder. In: Pavone- Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 267–270Google Scholar
  73. Hall RR (1980b) Methotrexate therapy for multiple T1 category bladder carcinoma. In: Pavone- Macaluso M, Smith PH, Edsymr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 337–380Google Scholar
  74. Hall RR, Turner AG (1980) Methotrexate treatment for advanced bladder cancer. A review after 6 years. Br J Urol 52: 403PubMedGoogle Scholar
  75. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461–463PubMedGoogle Scholar
  76. Hanna N (1981) Preparation of tumor cells for in vivo drug sensitivity testing. In: Proceedings of the UCLA Department of Microbiology and Immunology Workshop No 33, Los Angeles, California, 14–15 May, 1981Google Scholar
  77. Hanna N (1982) Nude mice as recipients for syngeneic, allogeneic and xenogeneic neoplasms. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, pp 165–174Google Scholar
  78. Herberman RB (1980) Summary—augmentation of NK activity. In: Herberman RB (ed) Natural cell mediated immunity against tumors. New York, Academic, pp 707–719Google Scholar
  79. Herr HW (1980) Diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 123: 853–855PubMedGoogle Scholar
  80. Herr HW, Bean MA, Whitmore WF (1978) Mixed leukocyte culture reactivity of lymph node cells regional to transitional cell carcinoma of the bladder. Natl Cancer Inst Monogr 49: 177–181PubMedGoogle Scholar
  81. Herr HW, Pinsky CM, Whitmore WF, Oettgen HF, Melamed MR (1983) Intravesical BCG therapy of superficial bladder tumors. In: Proceedings of the 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada, 19 April, 1983Google Scholar
  82. Hewitt CW, Shultz SM, Cole J, Miller JB, Martin DC (1982) Identification of bladder-cancer associated antigens by two dimensional gel immuno-electrophoresis. In: Proceedings of the 77th Annual Meeting of the American Urological Association, Kansas City, Missouri, 1982Google Scholar
  83. Higby DJ (1980) Chemotherapeutic management of bladder cancer. In: Aisner J, Chang P (eds) Cancer treatment research. Developments in oncology series, vol 2. Martinus Nijhoff, The Hague, pp 142–152Google Scholar
  84. Hollinshead AC (1978) Preliminary studies of sera and urine from patients with bladder cancer. Natl Cancer Inst Monogr 49: 193–198PubMedGoogle Scholar
  85. Hollister D, Coleman M (1980) Hematologic effects of intravesical thiotepa for bladder carcinoma. JAMA 244: 2065–2067PubMedGoogle Scholar
  86. Howe GR, Burch JO, Miller AD, Cook GM, Esteves J, Morrison B, Gordon P, Chambers LW, Fodor G, insor GM (1980) Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 64: 701–713PubMedGoogle Scholar
  87. Ikic D, Maricic Z, Oresic V, Rode B, Nola P, Smudj K, Knezevic M, Jusic D, Soos E (1981) Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet I: 1022–1024PubMedGoogle Scholar
  88. Jacobi GH, Kurth KH, Klipper KF, Hohenfellner R (1979) On the biological behavior of T1 transitional cell tumor of the urinary bladder and initial results of the prophylactic use of topical Adriamycin under controlled and randomized conditions. In: Diagnosis and treatment of superficial bladder tumors. Motedison, Stockholm, pp 83–94Google Scholar
  89. Jacobs SE, Lawson RK (1982) Pathological effects of precystectomy therapy with combination of doxorubicin hydrochloride and local bladder hyperthermia for bladder cancer. J Urol 127: 43–47PubMedGoogle Scholar
  90. Jakse G, Hofstadter F (1981) ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride. Urol Res 9: 153–159PubMedGoogle Scholar
  91. Jakse G, Hofstadter F, Marberger H (1981) Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 125: 185–190PubMedGoogle Scholar
  92. Jewett HJ, Strong GH (1946) Infiltrating carcinoma of the bladder. Relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 55: 366–372PubMedGoogle Scholar
  93. Jones WA, Gibbons RP, Correa RJ, Cummings KB, Mason JT (1980) Primary adenocarcinoma of the bladder. Urology 15: 119–122PubMedGoogle Scholar
  94. Kedia KR, Gibbons C, Persky L (1981) The management of advanced bladder carcinoma. J Urol 125: 655–658PubMedGoogle Scholar
  95. Kemeny N, Yagoda A, Wang Y, Field K, Wrobleski H, Whitmore W (1981) Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer. Cancer 48: 2154–2157PubMedGoogle Scholar
  96. Koontz WW (1979) Intravesical chemotherapy and chemoprevention of superficial, low grade, low stage bladder carcinoma. Semin Oncol 6: 217–219PubMedGoogle Scholar
  97. Koontz WW, Prout GR Jr, Smith W, Frable WJ, Minnis JE (1981) The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder. J Urol 125: 307–312PubMedGoogle Scholar
  98. Koontz WW, Heney N, Schmidt JD, Soloway M, Penick GD, Ahmed S, Prout G (1983) The ablative effect of intravesical Mitomycin C for thiotepa failures. In: Proceedings of the 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada, 19 April, 1983Google Scholar
  99. Koss LG (1975) Tumors of the urinary bladder. In: Koss (ed) Atlas of tumor pathology, fascicle 11, 2nd ser. Armed Forces Institute of Pathology, Washington DCGoogle Scholar
  100. Koss LG (1979) Tumors of the urinary tract and prostate. In: Koss LG (ed) Diagnostic cytology and its histological basis, 3rd edn. Lippincott, Philadelphia, p 684Google Scholar
  101. Kramer SA, Bredael J, Croker BP, Paulson DF, Glenn JF (1979) Primary non-urachal adenocarcinoma of the bladder. J Urol 121: 278–281PubMedGoogle Scholar
  102. Kurth KH, Tunn U, Ay R, Debruyne F, dePauw M, Sylvester R, Tenkate FW (1983) Phase II chemotherapy with Adriamycin or ethoglucid (Epodyl) for resected Ta and T1 papillary carcinoma of the bladder. In: Proceedings of the 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada, 19 April, 1983Google Scholar
  103. Lamm DL, Thor DE, Winters WD, Stogdill VO, Radwin H (1981) BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses. Cancer 48: 82–86PubMedGoogle Scholar
  104. Lange PH, Limas C, Fraley EE (1978) Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 119: 52–55PubMedGoogle Scholar
  105. Larsen J (1980) Inactivation of Epodyl in aluminium foil cups as a cause of ineffective treatment of non-invasive bladder tumors. Scan J Urol Nephrol 14: 239–242Google Scholar
  106. Lieber MM, Kovach JS (1981) Soft agar clonogenic assay for primary human renal carcinoma: in vitro chemotherapeutic drug sensitivity testing. In: Proceedings of the 76th Annual Meeting of the American Urological Association, Boston, Maryland, 1981Google Scholar
  107. Lindholm CE, Mattson W, Langeland P, Gunning I (1980) 5-Fluorouracil and Adriamycin in locally recurrent and/or metastatic bladder cancer. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 391–394Google Scholar
  108. Logothetis CT (1981) CISCA chemotherapy for bladder cancer. Cancer Bull 33: 79–80Google Scholar
  109. Malling N, Sorensen SS (1980) Adjuvant thiotepa in the treatment of bladder papillomata. A prospective randomized experiment ( Abstr ). Ugeskr Laeger 142: 1678–1679Google Scholar
  110. Martinez-Piñeiro JA (1980) Introduction to immunology and immunotherapy of bladder tumors. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 131–134Google Scholar
  111. Matsumoto K, Kakizoe T, Mikuriya S, Tanaka T, Kondo I, Umegaki Y (1981) Clinical evaluation of intraoperative radiotherapy for carcinoma of the urinary bladder. Cancer 47: 509–513PubMedGoogle Scholar
  112. Melloni D, Pavone-Macaluso M (1980) Intravesical treatment of superficial urinary bladder tumors with Adriamycin. In: Pavone-Macaluso M, Smith PH, Esmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 317–320Google Scholar
  113. Merrin CE (1979) Treatment of genitourinary tumors with cis-dichlorodiammineplatinum (II): experience in 250 patients. Cancer Treat Rep 63: 1570–1584Google Scholar
  114. Merrin CE, Cartagena R, Wajsman Z, Baumgartner G, Murphy GP (1975) Chemotherapy of bladder carcinoma with cyclophosphamide and Adriamycin. J Urol 114: 884–887PubMedGoogle Scholar
  115. Messing EM, Bubbers JE, Whitmore KE, deKernion JB, Fahey JL (1984) Murine hybridoma antibodies to human transitional cell carcinoma. J Urol (in press)Google Scholar
  116. Middleman E, Luce J, Frei E (1971) Clinical trials with Adriamycin. Cancer 28: 844–850PubMedGoogle Scholar
  117. Mishima T, Oda K, Murata S, Ooe H, Mori Y, Takahashi T (1975) Mitomycin C bladder instillation therapy for bladder tumors. J Urol 114: 217–219Google Scholar
  118. Mohiuddin M, Strong GH, Mulholland SG (1982) Combined pre and postoperative adjuvant radiotherapy for bladder cancer. Urology 19: 135–138PubMedGoogle Scholar
  119. Moore G, Bross ID, Ausman R, Nadler S, Jones R, Slack N, Reimm A (1963) Effects of 5-fluorouracil in 389 patients with cancer. Cancer Chemother Rep 27: 67–69Google Scholar
  120. Montesano R, Devron C, Kuroki T, Saint Vincent L, Handleman S, Sanford KK, Defeo D, Weinstein IB (1977) Test for malignant transformation of rat liver cells in culture: cytology, growth in soft agar, and production of plasminogen activator. J Natl Cancer Inst 59: 1651–1658PubMedGoogle Scholar
  121. Morales A (1980) Treatment of carcinoma in situ of the bladder with BCG: Phase II trial. Cancer Immunol Immunother 9: 69–72Google Scholar
  122. Morales A, Ersil A (1979) Prophylaxis of recurrent bladder cancer with Bacillus-Calmette-Guerin in cancer of the genitourinary tract. In: Johnson DE, Samuels ML (eds) Proceedings of the University of Texas Systems Cancer Center M D Anderson Hospital and Tumor Institute, 23rd Annual Conference in Cancer, Houston, Texas, November 1978. Raven, New York, p 121Google Scholar
  123. Morales A, Ottenhof P, Emerson L (1981) Treatment of residual non-infiltrating bladder cancer with Bacillus Calmette-Güerin. J Urol 125: 649–651PubMedGoogle Scholar
  124. Moriyama N, Ito K (1980) Light and electron microscopic changes in bladder tumor cells after intravesical instillation and hyperthermic vesical irrigation of Bleomycin (Abstr). Nippon, Hinyokika Gakkai Zasshi 71: 1371–1380Google Scholar
  125. Morrison AS, Buring JE, Verhouk WG, Aoki K, Leck I, Ohno Y, Obata K (1984) International study of smoking and bladder cancer. J Urol 131: 650–654PubMedGoogle Scholar
  126. Murphy WM, Soloway MS, Crabtree WM (1981) The morphologic effects of Mitomycin C in mammalian urinary bladder. Cancer 47: 2567–2574PubMedGoogle Scholar
  127. Nagata K (1980) Studies on the absorption of anticancer agents through the bladder—basis of instillation therapy—III. Urinary excretion and vesical tissue concentration of instilled Adriamycin in patients with bladder cancer (Abstr). Hinyokika Kiyo 26: 983–988Google Scholar
  128. Nakajima K, Hisazumi H, Uchibayashi T, Naito K, Misaki T, Kuroda K, Miyazaki K, Fujita Y, Taya T, Kameda K (1980) A combination therapy of hyperthermia and Bleomycin for bladder cancer ( Abstr ). Hinokika Kiyo 26: 1153–1161Google Scholar
  129. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW (1981) Methotrexate: an active drug in bladder cancer. Cancer 47: 1246–1250PubMedGoogle Scholar
  130. Needles B, Blumenreich M, Yagoda A, Sogani P, Whitmore WF (1981) Intravesical cis-platinum for superficial bladder cancer. Proc Am Assoc Cancer Res 22: 158, 625Google Scholar
  131. Nevin JE, Melnick I, Baggerly JT, Hoffman A, Landes RR, Easley C (1973) The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of carcinoma of the bladder and prostate. Cancer 31: 138–144PubMedGoogle Scholar
  132. Nielsen HV, Thybo E (1979) Epodyl treatment of bladder tumors. Scan J Urol Nephrol 13: 59–63Google Scholar
  133. Ogata J, Migita N, Nakamura T (1973) Treatment of carcinoma of the bladder by infusion of the anticancer agent ( Mitomycin C) via the internal iliac artery. J Urol 110: 667–670Google Scholar
  134. Ogawa H, Onodera Y, Watanabe M, Higaki Y, Yoshida H, Imamura K, Sugiyama Y (1980) Clinical effect of intravesical instillation with carboquone and cystosine arabinoside on superficial bladder tumors ( Abstr ). Hinyokika Kiyo 26: 1437–1448Google Scholar
  135. Okada K, Gon H, Nogaki J, Niimura T, Saito T, Amagai T, Yamamoto T, Kiyotaki S, Sato Y, Ogawa N, Morita H, Kitajima K, Kishimoto T (1980) Hyperthermic treatment for bladder tumors. Urokinase combination therapy ( Abstr ). Nishinippon Hinyokika 42: 967–971Google Scholar
  136. Oliver RTD (1980) The place of chemotherapy in the treatment of patients with invasive carcinoma of the bladder. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 381–385Google Scholar
  137. Peterson LT, Paulson DF, Bonar RA (1974) Response of human urothelium to chemical carcinogens in vitro. J Urol 111: 154–159PubMedGoogle Scholar
  138. Pontes JE, Dhawbwala CB, Pierce JM (1984) Intravesical Adriamycin therapy for bladder cancer—long-term results. Urology (Suppl). 23: 35–36Google Scholar
  139. Prout GR Jr, Bross ID, Slack NH, Ausman RK (1968) Carcinoma of the bladder. 5-Fluorouracil and the critical role of a placebo: a cooperative group report. I. Cancer 22: 926–931Google Scholar
  140. Prout GR Jr, Griffen, PP, Nocks BN, DeFuria MD, Daly JJ (1982) Intravesical therapy of low stage bladder carcinoma with Mitomycin C: comparison of results in untreated and previously treated patients. J Urol 127: 1096–1098PubMedGoogle Scholar
  141. Prout GR, Koontz WW, Coombs LJ, Hawkins IR, Friedell GH (1983) Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not receive thiotepa. J Urol 130: 677–680PubMedGoogle Scholar
  142. Richards B (1980) Adjuvant chemotherapy following primary irradiation in T3 tumors, and other topics in urological oncology. In: Pavone Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 395–397Google Scholar
  143. Richie JP, Blute RD, Waisman J (1980) Immunologic indications of prognosis in bladder cancer. The importance of cell surface antigens. J Urol 123: 22–24Google Scholar
  144. Riddle PR (1973) The management of superficial bladder tumors with intravesical Epodyl. Br J Urol 45: 84–87PubMedGoogle Scholar
  145. Riddle PR, Wallace DM (1971) Intracavitary chemotherapy for multiple non-invasive bladder tumors. Br J Urol 43: 181–184PubMedGoogle Scholar
  146. Robinson MGR, Shelty MB, Richards B, Bastaple J, Glashan RW, Smith PH (1977) Intravesical Epodyl in the management of bladder tumors. Combined experience of the Yorkshire Urological Cancer Group. J Urol 118: 972–973Google Scholar
  147. Sadoughi H, Rubenstone A, Misna J, Davidsohn I (1980) The cell surface antigens of bladder washing specimens in patients with bladder tumor. A new approach. J Urol 123: 19–21Google Scholar
  148. Sakamoto S, Ogata J, Ikegami K, Maeda H (1980) Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration. Eur J Cancer 16: 103–113PubMedGoogle Scholar
  149. Samuels ML, Logothetis C, Trindate A, Johnson DE (1980) Cytoxan, Adriamycin and cis-platinum ( CISCA) in metastatic bladder cancer. Proc Am Assoc Cancer Res 21: 137Google Scholar
  150. Sandberg AA (1980) Tumors of the urinary tract. In: Sandberg A A (ed) The chromosomes in human cancer and leukemia. Elsevier North Holland, New York, pp 503–511Google Scholar
  151. Sarna G (1979) Principles of chemotherapy. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, pp 14–39Google Scholar
  152. Schulman CC (1980) Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 347–354Google Scholar
  153. Schulman CC, Denis LJ, Wauters E (1980) Intravesical cis-platinum in bladder tumors: toxicity study. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) bladder tumors and other topics in urological oncology. Plenum, New York, pp 355–359Google Scholar
  154. Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF, Lesser M (1983) Phase II trial of sequentially administered cis-platinum, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130: 681–684PubMedGoogle Scholar
  155. Shin SI, Freedman VH, Risser R, Pollack R (1975) Tumorigenicity of virus transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435PubMedPubMedCentralGoogle Scholar
  156. Skinner DG, Kaufman JJ (1978) Management of invasive and high grade bladder cancer. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, p 268Google Scholar
  157. Smalley RU, Bartolucci AA, Hemstreet G, Hester M (1981) A Phase II evaluation of a 3 drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125: 191–195PubMedGoogle Scholar
  158. Smith PH (1980) The aims and activities of the EORTC Urological Group. In: Pavone-Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 35–40Google Scholar
  159. Soloway MS (1978) Cis-diamminedichloroplatinum (II) (DDP) in advanced bladder cancer. J Urol 120: 716–719Google Scholar
  160. Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 461–466PubMedGoogle Scholar
  161. Soloway MS (1982) Editorial comment. J Urol 127: 1098Google Scholar
  162. Soloway MS (1984) Editorial comment. J Urol 131: 49Google Scholar
  163. Soloway MS, Murphy WM, deFuria MD, Crooke S, Finebaum P (1981a) The effect of Mitomycin C on superficial bladder cancer. J Urol 125: 646–648PubMedGoogle Scholar
  164. Soloway MS, Ikard M, Ford K (1981b). Cis-diamminedichloroplatinum ( II) in locally advanced and metastatic urothelial cancer. Cancer 47: 476–480Google Scholar
  165. Stanisic TH, Buick RN, Salmon SE (1980a) Soft agar methylcellulose assay for human bladder carcinoma. In: Salmon SE (ed) Cloning of human tumor cells. Alan R Liss, New York, pp 75–84Google Scholar
  166. Stanisic TH, Buick RN, Trent JM, Fry SE, Salmon SE (1980b) In vitro clonal assay for bladder cancer: the biological potential of urothelium and determination of in vitro sensitivity to cytotoxic agents. Surg Forum 31: 585–587Google Scholar
  167. Stober U, Peter HH (1980) BCG immunotherapy for prevention of relapse in patients with bladder cancer? ( Abstr ). Therapiewoche 30: 6067–6070Google Scholar
  168. Storm FK (1982) Hyperthermia in cancer therapy. In: Proceedings of UCLA Interdepartmental Conference—New advances in oncology, Los Angeles, California, 4 March 1982Google Scholar
  169. Studer UE, Biedermann C, Chollet C, Karrer P, Kraft H, Toggenburg, Vonbank F (1984) Prevention of recurrent superficial bladder tumors by oral etretinate. Preliminary results of randomized, double-blind multicenter trial in Switzerland. J Urol 131: 47’49Google Scholar
  170. Sullivan RD (1962) Intraarterial methotrexate therapy: the dose, duration and route of administration of methotrexate in clinical cancer chemotherapy. In: Porter R, Wiltshaw E (eds) First symposium on methotrexate in the treatment of cancer. Wright, Bristol, pp 50–55Google Scholar
  171. Summers JL, Falor WH, Ward R (1981) A ten year analysis of chromosomes in non-invasive papillary carcinoma of the bladder. J Urol 125: 424–426Google Scholar
  172. Summers JL, Coon JS, Ward RM, Falor WH, Miller AW, Weinstein RS (1983) Prognosis in carcinoma of the urinary bladder based upon tissue group ABH and Thomsen-Friedenreich antigen status and karotype of the initial tumor. Cancer Res 43: 934–939PubMedGoogle Scholar
  173. Tannock IF (1978) Cell kinetics and chemotherapy. A critical review. Cancer Treat Rep 62: 1117–1133PubMedGoogle Scholar
  174. Tannock IF (1981) Selection of chemotherapeutic agents. In: Proceedings of the 7th Annual NBCP Investigators’ Workshop. Hershey, Pennsylvania, June 1981Google Scholar
  175. Turner AG, Hendry WF, Williams GB, Bloom HJG (1977) The treatment of advanced bladder cancer with methotrexate. Br J Urol 46: 431–438Google Scholar
  176. Utz DC, DeWeerd JH (1978) The management of low grade low stage carcinoma of the bladder. In: Skinner DG, deKernion JB (eds) Genitourinary cancer. Saunders, Philadelphia, pp 256–268Google Scholar
  177. Utz DC, Farrow GM (1980) Management of carcinoma in situ of the bladder: the case for surgical management. Urol Clin North Am 7: 533–541PubMedGoogle Scholar
  178. Utz DC, Hanna KA, Farrow GM (1970) The plight of the patient with carcinoma in situ of the bladder. J Urol 103: 160–164PubMedGoogle Scholar
  179. Uyama T (1980) Intravesical instillation of Adriamycin combined with low-dose irradiation for superficial bladder cancer. Urology 15: 584–587PubMedGoogle Scholar
  180. Uyama T, Nakamura S, Yamamoto A, Moriwaki S (1980) Treatment of advanced bladder cancer by intraarterial infusion of Adriamycin ( Abstr ). G an To Kagaku Ryoho 7: 1964–1970Google Scholar
  181. van der Werf-Messing B (1978) Cancer of the urinary bladder treated by interstitial radium implant. Int J Radiol Oncol Biol Phys 45: 373–378Google Scholar
  182. van der Werf-Messing B, Hop WCJ (1981) Carcinoma of the urinary bladder (category T1NXM0) Chemotherapy of Bladder Cancer treated either by radium implant or by transurethral resection only. Int J Radiol Oncol Biol Phys 7: 299–303Google Scholar
  183. Veenema RJ (1978) Editorial comment. J Urol 120: 1411Google Scholar
  184. Veenema RJ, Dean AL, Roberts M, Fingerhut B, Chowhury RK, Tarassoly H (1962) Bladder carcinoma treated by direct instillation of thiotepa. J Urol 88: 60–63PubMedGoogle Scholar
  185. von Hoff DD, Harris GJ, Johnson G, Glaubiger D (1980) Initial experience with the human tumor stem cell assay system: potential and problems. In: Salmon SE (ed) Cloning of human tumor stem cells. Alan R Liss, New York, pp 113–124Google Scholar
  186. Weinstein RS, Alroy J, Farrow GM, Miller AW, Davidsohn I (1979) Blood group isoantigen deletion in carcinoma in situ of the human bladder. Cancer 43: 661–668PubMedGoogle Scholar
  187. Whitmore WF (1980) Integrated irradiation and cystectomy for bladder cancer. Br J Urol 52: 1PubMedGoogle Scholar
  188. Whitmore WF, Batata MA, Ghoneim MS, Grabstald H, Unal A (1977) Radical cystectomy with or without prior irradiation for the treatment of bladder cancer. J Urol 118: 184–187PubMedGoogle Scholar
  189. Williams SD, Einhorn LH, Donohue JP (1979) Cis-platinum combination chemotherapy of bladder cancer. Cancer Clin Trials 2: 335 - 338Google Scholar
  190. Wilson WL (1960) Chemotherapy of human solid tumors with 5-fluorouracil. Cancer 13: 1230–1239PubMedGoogle Scholar
  191. Winters WD, Lamm DL (1981) Antibody responses to Bacillus-Calmette-Guerin during immu¬notherapy in bladder cancer patients. Cancer Res 41: 2672–2676PubMedGoogle Scholar
  192. Wright GL, Starling JJ, Sieg SM (1981) Monoclonal antibodies to tumor associated antigens in human prostate and bladder cancer. Fed Proc 40 (II): 995Google Scholar
  193. Yagoda A (1977) Future implications of Phase 2 chemotherapy trials in 95 patients with measurable advanced bladder cancer. Cancer Res 37: 2775–2780PubMedGoogle Scholar
  194. Yagoda A (1981) Chemotherapy of advanced bladder cancer. In: Conolly JG (ed) Carcinoma of the bladder. Raven Press, New York, pp 251–260Google Scholar
  195. Yagoda A, Watson RC, Whitmore WF (1980) Phase II trial of methotrexate in urinary bladder cancer. Proc Am Assoc Cancer Res 21: 427Google Scholar
  196. Young AK, Hammond B, Middleton AW (1979) The prognostic value of cell-surface antigens in low grade non-invasive transitional cell carcinoma of the bladder. J Urol 122: 462–464PubMedGoogle Scholar
  197. Young CW (1971) Interferon inducers in cancer. Med Clin North Am 55: 721–728PubMedGoogle Scholar
  198. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ (1983) Influence of thiotepa and doxorubicin instillation at the time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129: 505–509PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • E. Messing
  • J. B. deKernion

There are no affiliations available

Personalised recommendations